Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Oct 26, 2011, 05:35 ET from Reportlinker

NEW YORK, Oct. 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0661223/Growth-Hormone-Deficiency-GHD-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the Industry analysis specialist, has released its new report, "Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information on the global growth hormone deficiency therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global growth hormone deficiency therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global growth hormone deficiency sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global GHD therapeutics market values $1,354.5m in 2010, after increasing at a Compound Annual Growth Rate (CAGR) of 4.0% during 2005–2010. However, the market is expected to record a CAGR of 3.7% from 2010–2018, to value $1,804.7m by 2018. The growth recorded in GHD therapeutics market during 2005-2010, was primarily attributed to increase in the annual cost of therapy with the existing treatment options available. Apart from this, there are limited numbers of biosimilars formulation such as Omnitrope (somatropin), Valtropin (somatropin) in GHD therapeutics market. The launches of biosimilars have modest impact on the GHD therapeutics market because of availability of these products present at a competitive price. The Omnitrope was approved by the US Food and Drug Administration (US FDA) after long delays and court proceedings.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the growth hormone deficiency therapeutics market. Its scope includes -

- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) growth hormone deficiency therapeutics market revenue data for 2005–2010, and 2011–2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidate's fall under the therapy classes such as immunomodulator, anti-CD3 antibody, oral Insulin analogue, GLP-1 receptor agonist, interleukin-1 inhibitor, ultra-long acting insulin analogue, ultra-fast-acting insulin analogue, Insulin analogue and ultra rapid-acting insulin analogue.

- Analysis of the current and future competition in the seven key countries of the growth hormone deficiency therapeutics market. LG Life Sciences, BioPartners GmbH, Roche Group, Pfizer, Novo Nordisk, Astrazeneca, Ascendis Pharma A/S, Ipsen S.A., EMD Serono, Inc., Theratechnologies Inc, Eli Lilly and Company and Ambrx, Inc.they are key market players, is covered in this section.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the growth hormone deficiency therapeutics market.

- Analysis of key recent licensing and partnership agreements in growth hormone deficiency therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global growth hormone deficiency therapeutics market.

- Increase revenue through an understanding of the key trends, innovative products and technologies, market segments and companies likely to affect the global growth hormone deficiency therapeutics market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global growth hormone deficiency therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 7

2 Growth Hormone Deficieicny (GHD) Therapeutics: Executive Summary 9

2.1 GHD Therapeutics Market Forecast to Display Steady Growth until 2018 9

2.2 Significant Unmet Need in GHD Therapeutics Market, in Terms of Non Adherence to GH Therapy by Patients due to Complicated Dosage schedule 11

2.3 The Current Competition in the GHD Therapeutics Market is Strong with a Wide Range of Approved Products Available For the Treatment of GHD 12

2.4 Lack of Novel Therapies under Clinical Development to Render Scope of Entry for New Molecules with Improved Drug Delivery System 13

3 Growth Hormone Deficieicny (GHD) Therapeutics: Introduction 14

3.1 Disease Overview 14

3.2 Epidemiology 15

3.3 Etiology 16

3.4 Pathophysiology 17

3.5 Signs and Symptoms 18

3.6 Commonly Used Diagnostic Tests 19

3.7 Treatment and Management Options for Growth Hormone Deficiency 20

3.7.1 Factors affecting GH dosing 21

3.7.2 GH replacement therapy in adults with GHD: 22

3.7.3 GH replacement therapy in children with GHD: 23

3.8 GlobalData Pipeline Report Guidance 24

4 GHD Therapeutics: Market Characterization 25

4.1 GHD Therapeutics Market Size (2005–2010) – Global 25

4.2 GHD Therapeutics Market Forecast (2010–2018) – Global 27

4.3 GHD Therapeutics Market Size (2005–2010) – The US 29

4.4 GHD Therapeutics Market Forecast (2010–2018) – The US 30

4.5 GHD Therapeutics Market Size (2005–2010) – France 32

4.6 GHD Therapeutics Market Forecast (2010–2018) – France 33

4.7 GHD Therapeutics Market Size (2005-2010) – Germany 34

4.8 GHD Therapeutics Market Forecast (2010–2018) – Germany 36

4.9 GHD Therapeutics Market Size (2005–2010) – Italy 37

4.10 GHD Therapeutics Market Forecast (2010–2018) – Italy 38

4.11 GHD Therapeutics Market Size (2005–2010) – Spain 40

4.12 GHD Therapeutics Market Forecast (2010–2018) – Spain 41

4.13 GHD Therapeutics Market Size (2005–2010) – The UK 42

4.14 GHD Therapeutics Market Forecast (2010–2018) – The UK 43

4.15 GHD Therapeutics Market Size (2005–2010) – Japan 44

4.16 GHD Therapeutics Market Forecast (2010–2018) – Japan 45

4.17 Drivers and Barriers for the GHD Therapeutics Market 47

4.17.1 Drivers for the GHD Therapeutics Market 47

4.17.2 Barriers for the GHD Therapeutics Market 48

4.18 Opportunity and Unmet Need Analysis 49

4.19 Key Takeaway 50

5 GHD Therapeutics: Competitive Assessment 51

5.1 Overview 51

5.2 Strategic Competitor Assessment 51

5.3 Product Profiles for the Major Marketed Products in the GHD Therapeutics Market 53

5.3.1 Nutropin AQ 53

5.3.2 Humatrope 54

5.3.3 Genotropin 55

5.3.4 Saizen 57

5.3.5 Norditropin 58

5.3.6 Omnitrope 59

5.3.7 Increlex 60

5.4 Key Takeaway 61

6 GHD Therapeutics: Pipeline Assessment 62

6.1 Overview 62

6.2 Strategic Pipeline Assessment 62

6.3 GHD Therapeutics Pipeline – Pipeline by Phases of Development 63

6.3.1 GHD Therapeutics –Regulatory Filed and Phase III Clinical Pipeline 63

6.3.2 GHD Therapeutics – Phase II Pipeline 63

6.3.3 GHD Therapeutics – Phase I Pipeline 64

6.3.4 GHD Therapeutics – Preclinical 64

6.3.5 GHD Therapeutics – Discovery 64

6.3.6 GHD Therapeutics – Unknow Phase 64

6.3.7 Technology Trends Analytic Framework 64

6.4 GHD Therapeutics Market – Pipeline by Mechanism of Action 66

6.5 GHD Therapeutics – Promising Drugs in Clinical Development 67

6.6 Molecule Profile for Promising Drugs in Clinical Development 68

6.6.1 LB03002 (SR-rhGH) 68

6.7 Key Takeaway 69

7 GHD Therapeutics: Clinical Trials Mapping 70

7.1 Clinical Trials by Region and Country 70

7.2 Clinical Trials by Phase 71

7.3 Clinical Trials by Trial Status 72

7.4 Clinical Trials Mapping by Sponsors 73

7.5 Prominent Sponsors 74

7.6 Top Companies Participating in GHD Therapeutics Clinical Trials 75

8 GHD Therapeutics: Strategic Assessment 77

8.1 Key Events Impacting the Future Market 77

8.2 GHD Therapeutics: Implications for Future Market Competition 77

9 GHD Therapeutics Market: Future Players 80

9.1 Introduction 80

9.2 Company Profiles 81

9.2.1 BioPartners GmbH 81

9.2.2 LG Life Sciences, Ltd. 82

9.2.3 Ipsen S.A. 82

9.2.4 EMD Serono, Inc. 84

9.2.5 Theratechnologies Inc. 85

9.2.6 Ipsen S.A. 86

9.2.7 Eli Lilly and Company 87

9.2.8 Ambrx, Inc. 88

10 GHD Therapeutics: Licensing and Partnership Deals 89

11 GHD Therapeutics: Appendix 92

11.1 Market Definitions 92

11.2 Acronyms 92

11.3 Research Methodology 93

11.3.1 Coverage 93

11.3.2 Secondary Research 93

11.3.3 Forecasting 94

11.3.4 Primary Research 96

11.3.5 Expert Panel Validation 97

11.4 Contact Us 97

11.5 Disclaimer 97

11.6 Bibliography 98

List of Tables

Table 1: Major Marketed Products in The US and EU5 22

Table 2: GH Replacement Therapy in Adults with GHD 22

Table 3: GHD Therapeutics Market, Global, Revenue ($m), 2005–2010 26

Table 4: GHD Therapeutics Market, Global, Forecast ($m), 2010–2018 28

Table 5: GHD Therapeutics Market, The US, Revenue ($m), 2005–2010 29

Table 6: GHD Therapeutics Market, The US, Forecasts ($m), 2010–2018 31

Table 7: GHD Therapeutics Market, France, Revenue ($m), 2005–2010 33

Table 8: GHD Therapeutics Market, France, Forecasts ($m), 2010–2018 34

Table 9: GHD Therapeutics Market, Germany, Revenue ($m), 2005–2010 35

Table 10: GHD Therapeutics Market, Germany, Forecasts ($m), 2010–2018 37

Table 11: GHD Therapeutics Market, Italy, Revenue ($m), 2005–2010 38

Table 12: GHD Therapeutics Market, Italy, Forecasts ($m), 2010–2018 39

Table 13: GHD Therapeutics Market, Spain, Revenue ($m), 2005–2010 40

Table 14: GHD Therapeutics Market, Spain, Forecasts ($m), 2010–2018 42

Table 15: GHD Therapeutics Market, The UK, Revenue ($m), 2005–2010 43

Table 16: GHD Therapeutics Market, The UK, Forecasts ($m), 2010–2018 44

Table 17: GHD Therapeutics Market, Japan, Revenue ($m), 2005–2010 45

Table 18: GHD Therapeutics Market, Japan, Forecasts ($m), 2010–2018 46

Table 19: Pharmaceutical Company's Patient Assistance Programs 47

Table 20: Major Marketed Products in GHD Therapeutics Market 51

Table 21: GHD Therapeutics– Regulatory Filed and Phase III Pipeline, 2011 63

Table 22: GHD Therapeutics – Phase II Pipeline, 2011 63

Table 23: GHD Therapeutics – Phase I Pipeline, 2011 64

Table 24: GHD Therapeutics – Preclinical Phase Pipeline, 2011 64

Table 25: GHD Therapeutics – Discovery Phase Pipeline, 2011 64

Table 26: GHD Therapeutics – Unknown Phase, 2011 64

Table 27: GHD Therapeutics – Most Promising Drug In Clinical Development, 2011 67

Table 28: GHD Therapeutics – Clinical Trials by Country, 2011 71

Table 29: GHD Therapeutics – Clinical Trials by Phase, 2011 72

Table 30: GHD Therapeutics – Clinical Trials by Status, 2011 73

Table 31: GHD Therapeutics – Overall Sponsors, 2011 73

Table 32: GHD Therapeutics – Prominent Sponsors, 2011 74

Table 33: GHD Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 76

Table 34: BioPartners GmbH, Pipeline – 2011 82

Table 35: LG Life Sciences, Pipeline– 2011 82

Table 36: Ipsen S.A., Pipeline– 2011 84

Table 37: EMD Serono, Inc., Pipeline– 2011 85

Table 38: Theratechnologies Inc., Pipeline– 2011 86

Table 39: Ipsen S.A., Pipeline– 2011 87

Table 40: Ambrx, Inc., Pipeline– 2011 88

Table 41: GHD–Global, Deals, 2011 89

List of Figures

Figure 1: GHD Therapeutics Market, Global, Revenue and Forecasts ($m), 2005–2018 10

Figure 2: Opportunity and Unmet Need in the GHD Therapeutics Market 12

Figure 3: Etiology of Growth Hormone Deficiency 16

Figure 4: Re-evaluation of GH and IGF-1 Levels– End of Growth in GHD Children 21

Figure 5: GHD Therapeutics Market, Global, Revenue ($m), 2005–2010 26

Figure 6: GHD Therapeutics Market, Global, Forecast ($m), 2010–2018 28

Figure 7: GHD Therapeutics Market, The US, Forecast ($m), 2005–2010 29

Figure 8: GHD Therapeutics Market, The US, Forecasts ($m), 2010–2018 31

Figure 9: GHD Therapeutics Market, France, Revenue ($m), 2005–2010 32

Figure 10: GHD Therapeutics Market, France, Forecast ($m), 2010–2018 34

Figure 11: GHD Therapeutics Market, Germany, Revenue ($m), 2005–2010 35

Figure 12: GHD Therapeutics Market, Germany, Forecast ($m), 2010–2018 37

Figure 13: GHD Therapeutics Market, Italy, Revenue ($m), 2005–2010 38

Figure 14: GHD Therapeutics Market, Italy, Forecast ($m), 2010–2018 39

Figure 15: GHD Therapeutics Market, Spain, Revenue ($m), 2005–2010 40

Figure 16: GHD Therapeutics Market, Spain, Forecast ($m), 2010–2018 41

Figure 17: GHD Therapeutics Market, The UK, Revenue ($m), 2005–2010 42

Figure 18: GHD Therapeutics Market, The UK, Forecast ($m), 2010–2018 44

Figure 19: GHD Therapeutics Market, Japan, Revenue ($m), 2005–2010 45

Figure 20: GHD Therapeutics Market, Japan, Forecasts ($m), 2010–2018 46

Figure 21: Barriers To The Development of Biogenerics 48

Figure 22: Opportunity and Unmet Need in the GHD Therapeutics Market 50

Figure 23: GHD Therapeutics – Strategic Competitor Assessment, 2011 52

Figure 24: GHD Therapeutics – Pipeline by Phase of Development, 2011 63

Figure 25: GHD Therapeutics – Technology Trends Analytics Framework, 2011 65

Figure 26: GHD Therapeutics – Technology Trends Analytics Framework – Description, 2011 66

Figure 27: GHD Therapeutics – Pipeline by Mechanism of Action, 2011 67

Figure 28: GHD Therapeutics – Clinical Trials by Country, 2011 70

Figure 29: GHD Therapeutics – Clinical Trials by Phase, 2011 71

Figure 30: GHD Therapeutics – Clinical Trials by Status, 2011 72

Figure 31: GHD Therapeutics– Overall Sponsors, 2011 73

Figure 32: GHD Therapeutics – Prominent Sponsors, 2011 74

Figure 33: GHD Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 75

Figure 34: GHD Therapeutics Market, Drivers and Barriers, 2011 77

Figure 35: Implications for Future Market Competition in the GHD Therapeutics Market, 2011 78

Figure 36: GHD Therapeutics Market– Clinical Pipeline by Company, 2011 80

Figure 37: GlobalData Market Forecasting Model 96BioPartners GmbH

LG Life Sciences, Ltd.

Ipsen S.A.

EMD Serono, Inc.

Theratechnologies Inc.

Ipsen S.A.

Eli Lilly and Company

Ambrx, Inc.

To order this report:

Biopharmaceutical Industry: Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Biopharmaceutical Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com